What do the New Clinical Trials on COPD Mean for You? - Canadian Council On Continuing Education In Pharmacy (CCCEP)


1 hr



# of Credits




Expiry Date


The findings from recent clinical trials have important implications for the pharmacologic management of chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. In Canada, COPD approximately 4% of Canadians have been diagnosed with COPD, but the actual prevalence is estimated to be much higher. This educational program will discuss recent studies involving the pharmacologic management of COPD, and current treatment recommendations.

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.00 CEU(s). CCCEP File Number: 1066-2018-2581-I-P

Gordon Dyck, MD, MCFP, BSc(Med), BA
Simon Lessard, B.Pharm, MBA, CRE, CTE
Hema Rajawat, BSc. Pharm, RPh

On completion of this program, participants should be able to:

  • Describe the management of COPD as per the GOLD 2018 report and the CTS 2017 position statement
  • Describe the FLAME study and the role of dual LABA/LAMA therapy in COPD
  • Discuss the IMPACT study and the role triple combination therapy in COPD
  • Apply follow-up strategies to ensure proper long-term management of COPD patients

Related Courses